Role of myokines and osteokines in cancer cachexia.
Muscle
bone
cachexia
cancer
myokines
osteokines
Journal
Experimental biology and medicine (Maywood, N.J.)
ISSN: 1535-3699
Titre abrégé: Exp Biol Med (Maywood)
Pays: England
ID NLM: 100973463
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
pubmed:
27
4
2021
medline:
15
12
2021
entrez:
26
4
2021
Statut:
ppublish
Résumé
Cancer-induced muscle wasting, i.e. cachexia, is associated with different types of cancer such as pancreatic, colorectal, lung, liver, gastric and esophageal. Cachexia affects prognosis and survival in cancer, and it is estimated that it will be the ultimate cause of death for up to 30% of cancer patients. Musculoskeletal alterations are known hallmarks of cancer cachexia, with skeletal muscle atrophy and weakness as the most studied. Recent evidence has shed light on the presence of bone loss in cachectic patients, even in the absence of bone-metastatic disease. In particular, we and others have shown that muscle and bone communicate by exchanging paracrine and endocrine factors, known as myokines and osteokines. This review will focus on describing the role of the most studied myokines, such as myostatin, irisin, the muscle metabolite β-aminoisobutyric acid, BAIBA, and IL-6, and osteokines, including TGF-β, osteocalcin, sclerostin, RANKL, PTHrP, FGF23, and the lipid mediator, PGE
Identifiants
pubmed: 33899538
doi: 10.1177/15353702211009213
pmc: PMC8524772
doi:
Substances chimiques
Neuropeptides
0
myokinin
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2118-2127Références
J Diabetes Complications. 2020 Jan;34(1):107469
pubmed: 31706805
Cell. 2018 Dec 13;175(7):1756-1768.e17
pubmed: 30550785
Onco Targets Ther. 2020 May 19;13:4423-4430
pubmed: 32547073
Ann Surg Oncol. 2012 Apr;19(4):1350-6
pubmed: 21519918
Endocr Rev. 2020 Aug 1;41(4):
pubmed: 32393961
Front Physiol. 2019 Feb 18;10:41
pubmed: 30833900
J Support Oncol. 2003 Sep-Oct;1(3):159-68
pubmed: 15334872
FASEB J. 2021 Feb;35(2):e21335
pubmed: 33527503
Nature. 2014 Sep 4;513(7516):100-4
pubmed: 25043053
Sci Rep. 2017 Oct 31;7(1):14470
pubmed: 29089584
Bone. 2015 Nov;80:109-114
pubmed: 26453500
Front Physiol. 2016 Oct 19;7:472
pubmed: 27807421
J Musculoskelet Neuronal Interact. 2010 Mar;10(1):71-6
pubmed: 20190382
Peptides. 2017 Feb;88:62-66
pubmed: 28012856
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Nature. 2012 Jan 11;481(7382):463-8
pubmed: 22237023
Int J Mol Sci. 2021 Feb 02;22(3):
pubmed: 33540821
J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):507-509
pubmed: 27891294
J Bone Miner Res. 2018 Dec;33(12):2099-2113
pubmed: 30476357
QJM. 2016 Dec;109(12):785-790
pubmed: 27256459
Front Physiol. 2018 Sep 10;9:1125
pubmed: 30246803
Matrix Biol. 2010 Sep;29(7):638-44
pubmed: 20619344
Cell Metab. 2016 Jun 14;23(6):1078-1092
pubmed: 27304508
Eur J Transl Myol. 2018 Jun 04;28(2):7587
pubmed: 29991991
JBMR Plus. 2017 Oct;1(2):86-100
pubmed: 29104955
Nat Commun. 2012 Jan 17;3:630
pubmed: 22252554
Clin Nutr. 2021 Apr;40(4):2443-2455
pubmed: 33190987
Dis Model Mech. 2020 Jan 24;13(1):
pubmed: 31915140
Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12457-61
pubmed: 9356471
J Clin Invest. 2019 May 23;129(8):3214-3223
pubmed: 31120440
PLoS One. 2011;6(7):e22538
pubmed: 21799891
Bone. 2019 Mar;120:212-218
pubmed: 30408611
Cell Metab. 2012 Aug 8;16(2):153-66
pubmed: 22795476
Cell Metab. 2014 Jan 7;19(1):96-108
pubmed: 24411942
J Cachexia Sarcopenia Muscle. 2018 Aug;9(4):685-700
pubmed: 30009406
Skelet Muscle. 2012 Jul 06;2:14
pubmed: 22769563
J Cachexia Sarcopenia Muscle. 2020 Dec;11(6):1779-1798
pubmed: 33200567
Cell Rep. 2018 Feb 6;22(6):1531-1544
pubmed: 29425508
Diabetologia. 2015 Sep;58(9):2096-105
pubmed: 26105792
J Musculoskelet Neuronal Interact. 2002 Dec;2(6):570-2
pubmed: 15758398
Nat Med. 2015 Nov;21(11):1262-1271
pubmed: 26457758
Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15233-8
pubmed: 8986793
JCI Insight. 2019 Apr 9;5:
pubmed: 30965315
J Physiol. 2000 Nov 15;529 Pt 1:237-42
pubmed: 11080265
Am Fam Physician. 2003 May 1;67(9):1959-66
pubmed: 12751658
J Bone Miner Metab. 2014 Jul;32(4):378-92
pubmed: 24122251
Hum Mol Genet. 2019 Sep 15;28(18):3101-3112
pubmed: 31179501
Mol Ther Oncolytics. 2020 Jan 11;16:134-146
pubmed: 32055677
Science. 2002 May 24;296(5572):1486-8
pubmed: 12029139
Front Endocrinol (Lausanne). 2019 Aug 07;10:543
pubmed: 31447786
J Biol Chem. 2017 Jun 30;292(26):11021-11033
pubmed: 28465350
Science. 2021 Jan 29;371(6528):
pubmed: 33303683
Am J Physiol Endocrinol Metab. 2018 Oct 1;315(4):E594-E604
pubmed: 29558205
Jpn J Clin Oncol. 2002 Oct;32(10):422-4
pubmed: 12451040
Lancet Oncol. 2003 Nov;4(11):686-94
pubmed: 14602249
Biomedicines. 2021 Jan 12;9(1):
pubmed: 33445754
Nat Commun. 2017 Oct 24;8(1):1104
pubmed: 29062100
Nat Rev Cancer. 2014 Nov;14(11):754-62
pubmed: 25291291
Curr Osteoporos Rep. 2020 Aug;18(4):401-407
pubmed: 32514668
Bone. 2019 Nov;128:115053
pubmed: 31473261
Exp Oncol. 2018 Jun;40(2):136-139
pubmed: 29949526
Cell Cycle. 2015;14(10):1507-16
pubmed: 25785867
Future Oncol. 2012 Jul;8(7):803-17
pubmed: 22830401
Annu Rev Med. 2010;61:91-104
pubmed: 20059333
Cancers (Basel). 2019 Oct 11;11(10):
pubmed: 31614634
J Clin Invest. 2005 Sep;115(9):2322-4
pubmed: 16138187
Int J Cancer. 2005 Sep 1;116(3):471-8
pubmed: 15800941
Proc Natl Acad Sci U S A. 2015 Sep 29;112(39):12157-62
pubmed: 26374841
J Clin Invest. 2020 Jun 1;130(6):2888-2902
pubmed: 32078586
BMC Cancer. 2015 Nov 11;15:898
pubmed: 26560078
Bone. 2007 Jun;40(6):1544-53
pubmed: 17383950
J Appl Physiol (1985). 2005 Dec;99(6):2075-9
pubmed: 16099893
Best Pract Res Clin Endocrinol Metab. 2008 Feb;22(1):107-18
pubmed: 18279783
Int J Nephrol. 2020 Feb 10;2020:4596920
pubmed: 32095286
J Bone Miner Res. 2014 Jun;29(6):1369-72
pubmed: 24347438
Am J Physiol Endocrinol Metab. 2013 Apr 15;304(8):E863-73
pubmed: 23443925
Int J Obes (Lond). 2014 Dec;38(12):1538-44
pubmed: 24614098
Inflamm Regen. 2020 Feb 7;40:2
pubmed: 32047573
Curr Opin Support Palliat Care. 2018 Dec;12(4):420-426
pubmed: 30124526
Front Endocrinol (Lausanne). 2019 Nov 19;10:809
pubmed: 31803146
Endocrine. 2018 Feb;59(2):260-274
pubmed: 29170905
Eur J Clin Invest. 2008 Jul;38(7):531-8
pubmed: 18578694
J Clin Invest. 1992 May;89(5):1681-4
pubmed: 1569207
Cancer Res. 1982;42(2 Suppl):721s-726s
pubmed: 7055813
Nat Med. 2015 Sep;21(9):1085-90
pubmed: 26236992
Exerc Sport Sci Rev. 2010 Oct;38(4):168-76
pubmed: 20871233
Adv Immunol. 1993;54:1-78
pubmed: 8379461
Am J Physiol Cell Physiol. 2016 Apr 15;310(8):C663-72
pubmed: 26825123
J Cachexia Sarcopenia Muscle. 2020 Aug;11(4):947-961
pubmed: 32125790
Bone. 2012 Jan;50(1):104-10
pubmed: 21986000
J Cell Mol Med. 2018 Feb;22(2):1329-1336
pubmed: 29247983
Annu Rev Cell Dev Biol. 2001;17:311-50
pubmed: 11687492
Br J Cancer. 1999 Mar;79(7-8):1179-81
pubmed: 10098755
J Orthop Res. 2008 Sep;26(9):1238-44
pubmed: 18404722
Differentiation. 2009 Jan;77(1):12-8
pubmed: 19281760
Curr Sports Med Rep. 2012 Nov-Dec;11(6):328-34
pubmed: 23147022
Cell Death Dis. 2021 Jan 28;12(1):134
pubmed: 33510128
Cell Metab. 2008 Jan;7(1):33-44
pubmed: 18177723
Am J Physiol Cell Physiol. 2009 Jun;296(6):C1258-70
pubmed: 19357233
Sci Rep. 2017 May 17;7(1):2046
pubmed: 28515477
J Bone Miner Res. 2011 Jul;26(7):1425-36
pubmed: 21312267
Mol Metab. 2016 Jul 16;5(10):1042-1047
pubmed: 27689017
Clin Nutr. 2012 Aug;31(4):562-6
pubmed: 22348869
Arq Bras Cardiol. 2018 Jul;111(1):39-47
pubmed: 29972412
Curr Cancer Drug Targets. 2009 Aug;9(5):608-16
pubmed: 19508174